MANCHESTER, NH--(Marketwired - Apr 8, 2013) -  Boston Therapeutics, Inc. (OTCQB: [ BTHE ]) ("Boston Therapeutics" or "the Company"), a pharmaceutical company focused on developing and commercializing complex carbohydrate-based drugs to treat diabetes and inflammatory diseases, has been featured in four publications in recent weeks.

On April 3, InformationAboutDiabetes.com published an article titled "Boston Therapeutics On The Verge of a Blood Sugar Breakthrough -- An Interview With CEO Dr. Platt." In the interview, David Platt, Ph.D., CEO of Boston Therapeutics, discusses the chemistry of PAZ320, the Company's complex carbohydrate drug candidate for lowering the elevation of post-prandial glucose (PPG)or post-meal sugar levels.

On March 30, Mike Cote, business editor of the New Hampshire Union Leader, published a column in print and online titled "CEO Says Sugar Kills, and He's Working on a Solution." It highlights Dr. Platt's concern over the popularity of sugar-based products and the Company's development of PAZ320 and IPOXYN, a glycoprotein anti-necrosis drug developed to help improve blood flow to lower limbs.

On March 29, Western Pennsylvania Healthcare News published an article by Dr. Platt on its website titled "Complex Carbohydrate Chemistry: A Key for Unmet Medical Needs." Dr. Platt highlights a range of Company initiatives including the development of PAZ320 and IPOXYN.

On March 14, Examiner.com published an article titled "Good News for Metformin Users." It highlights PAZ320 and its potential to help those with type 2 diabetes.

To read the InformationAboutDiabetes.com article, please visit: [ www.informationaboutdiabetes.com/share/treatment/science-and-research/boston-therapeutics-on-the-verge-of-a-blood-sugar-breakthrough- ]

To read the New Hampshire Union Leader column, please visit:
[ www.newhampshire.com/article/20130331/NEWS02/130339967 ]

To read the Western Pennsylvania Healthcare News article, please visit:
[ www.wphealthcarenews.com/complex-carbohydrate-chemistry-a-key-for-unmet-medical-needs/ ]

To read the Examiner.com article, please visit:
[ www.examiner.com/article/good-news-for-metformin-users ]

About Boston Therapeutics, Inc.

Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: [ BTHE ]) is a leader in the field of complex carbohydrate chemistry. The Company's product pipeline is focused on developing and commercializing therapeutic molecules for diabetes, including PAZ320, a non-systemic chewable therapeutic compound designed to reduce the elevation of post-prandial glucose (PPG) or post-meal blood sugar, and IPOXYN, an injectable anti-necrosis drug specifically designed to treat lower limb ischemia associated with diabetes. More information is available at [ www.bostonti.com ].

Forward Looking Statements

Any statements in this news release about future expectations, plans and prospects for the Company constitute forward-looking statements as defined in the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those described in such statements.

More information about those risks and uncertainties is contained and discussed in the Company's most recent quarterly or annual report and in the Company's other reports filed with the Securities and Exchange Commission. The forward-looking statements represent the Company's views as of the date of this news release and should not be relied upon to represent the Company's views as of a subsequent date. While the Company anticipates that subsequent events may cause the Company's views to change, the Company disclaims any obligation to update such forward-looking statements.